HomeSequana Medical AG

Sequana Medical AG

alfapump: Phase 3 Data Show Implantable Pump Treats Liver Disease Complications

alfapump: Positive interim results from the first 13 patients in the Roll-In Cohort of the North American pivotal POSEIDON study of the alfapump for the treatment of recurrent or refractory ascites due to liver cirrhosis show positive outcomes against all primary endpoints of the study[1], as well as indications of clinically relevant improvements in quality of life measures.

Publication of Results of Multicenter Randomized Controlled Study: Patients with Refractory Ascites Treated with alfapump® System have Better Health-Related Quality of Life as Compared to Those Treated with Large Volume Paracentesis

3/19/18: The study demonstrated that patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis.